|1.||Akizawa, Tadao: 9 articles (06/2015 - 06/2002)|
|2.||Fukagawa, Masafumi: 8 articles (06/2015 - 09/2003)|
|3.||Hirata, Michinori: 6 articles (05/2015 - 09/2003)|
|4.||Shiizaki, Kazuhiro: 5 articles (11/2009 - 09/2003)|
|5.||Hatamura, Ikuji: 5 articles (11/2009 - 09/2003)|
|6.||Kinugasa, Eriko: 3 articles (06/2015 - 06/2007)|
|7.||Tominaga, Yoshihiro: 3 articles (06/2015 - 04/2006)|
|8.||Shinohara, Masami: 3 articles (05/2015 - 01/2013)|
|9.||Kono, Keiji: 3 articles (05/2015 - 01/2013)|
|10.||Nishi, Shinichi: 3 articles (05/2015 - 01/2013)|
04/01/2007 - "Injection of maxacalcitol (OCT) directly into the parathyroid gland (PTG) is a clinically safe and effective treatment for advanced secondary hyperparathyroidism (A-SHPT) resistant to conventional medical treatment. "
04/01/2004 - "Thus, iPTH measurement has a potential risk to overestimate 1-84PTH levels when evaluating the efficacy of maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism."
10/01/2011 - "A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism."
12/01/2004 - "Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism."
02/01/2010 - "Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism."
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
08/01/1999 - "This study indicates that once-daily maxacalcitol ointment is effective in the management of plaque psoriasis, with greatest effect noted at 25 microg/g. "
08/01/1999 - "To determine clinical efficacy, a phase II double-blind, randomized, left vs. right, concentration-response study was performed with once-daily topical maxacalcitol in patients with mild to moderate chronic plaque psoriasis. "
08/01/1999 - "Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator."
02/01/2014 - "Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis."
04/01/2009 - "When the Psoriasis Area and Severity Index (PASI) score revealed over a 75% decrease against the initial value, the administration of CyA MEPC was tapered off, and a topical application of maxacalcitol ointment was continued for the maintenance phase. "
03/19/2004 - "The suppression of urinary excretion of deoxypyridinoline, an index of bone resorption capacity of osteoclast, was greater in the 14HALO trial, which indicates that the efficacy of 22-oxacalcitriol for suppressing bone resorption might vary with the dosing time. "
11/01/1995 - "22-Oxacalcitriol (10(-10) and 10(-8) mol/l) significantly stimulated bone resorption, although to a slightly lesser degree than did calcitriol. "
09/01/1998 - "The present study was undertaken: to compare the therapeutic efficacy of a vitamin D analog, 22-oxa-1,25-dihydroxyvitamin D3 (OCT), and a bisphosphonate (disodium 3-amino-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate [AHPrBP]), an inhibitor of osteoclastic bone resorption, on cancer-induced hypercalcemia; and to see if the effect could be enhanced by combination treatment, using a nude mouse model implanted with a human pancreas carcinoma (FA-6). "
|4.||Osteosarcoma (Osteogenic Sarcoma)
02/01/2000 - "The highly metastasizing POS (HMPOS) canine osteosarcoma cell line which preferentially metastasize to the lungs was used to test the possible efficacy of 22-oxa-calcitriol (OCT) and all- trans retinoic acid (ATRA) to inhibit growth and pulmonary metastasis of the subcutaneously grown osteosarcoma in nude mice. "
02/01/2000 - "Inhibitory effects of 22-oxa-calcitriol and all- trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo."
04/12/1996 - "In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines."
11/01/1999 - "Induction of functional differentiation and growth inhibition in vitro of canine osteosarcoma by 22-oxacalcitriol, calcitriol and all-trans retinoic acid."
03/01/2000 - "The efficacy of 22-oxacalcitriol (OCT), calcitriol, cholecalciferol, all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cis RA) to differentiate in vitro four clonal cells of the canine osteosarcoma cell line POS into cells having properties of a functionally mature osteoblast bone cell were investigated. "
|5.||Hypercalcemia (Milk Alkali Syndrome)
06/01/2015 - "Primary efficacy analysis indicated that 27.7% in the paricalcitol group vs. 30.5% in the maxacalcitol group (95% CI -14.34% to 8.79%, P = 0.353) achieved target iPTH in the last 3 weeks without hypercalcemia during treatment, failing to achieve the non-inferiority margin of -5% that was set based upon agreement with the PMDA. "
01/01/2002 - "Serum calcium phosphorous concentration increased significantly, and maxacalcitol administration was interrupted because of hypercalcemia in 17 patients(18.5%). "
01/01/1992 - "Prostacyclin synthesis by aortic rings of rats treated with 22-oxa-1,25-dihydroxyvitamin D3 was much higher than that of non-treated controls, but did not cause any significant hypercalcemia. "
10/01/2005 - "In vivo, maxacalcitol inhibited the growth of BxPC-3 xenografts more significantly than calcitriol, without inducing hypercalcemia. "
05/01/1996 - "In vivo, 22-oxa-calcitriol inhibited the growth of BxPC-3 xenografts more significantly than calcitriol without including hypercalcemia. "
|2.||Cholecalciferol (Vitamin D3)
|5.||Tretinoin (Retinoic Acid)
|6.||Calcitriol Receptors (Calcitriol Receptor)
|8.||1 alpha,24-dihydroxyvitamin D3 (Tacalcitol)
|1.||Renal Dialysis (Hemodialysis)
|4.||Continuous Ambulatory Peritoneal Dialysis (CAPD)